BIOMAT Database Logo BIOMAT Database Logo

The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target. 2011

Theodore S Nowicki, and Augustine L Moscatello, and Edward Shin, and Stimson Schantz, and Raj K Tiwari, and Jan Geliebter
Department of Microbiology, New York Medical College, Valhalla, New York 10595, USA.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009536 Niacinamide An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. Nicotinamide,Vitamin B 3,Vitamin PP,3-Pyridinecarboxamide,Enduramide,Nicobion,Nicotinsäureamid Jenapharm,Papulex,Vitamin B3,3 Pyridinecarboxamide,B 3, Vitamin,B3, Vitamin,Jenapharm, Nicotinsäureamid
D010671 Phenylurea Compounds Compounds that include the amino-N-phenylamide structure. Phenylcarbamides,Phenylurea Derivatives,Compounds, Phenylurea,Derivatives, Phenylurea
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002291 Carcinoma, Papillary A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed) Carcinomas, Papillary,Papillary Carcinoma,Papillary Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077157 Sorafenib A niacinamide and phenylurea derivative that inhibits multiple intracellular and cell surface kinases thought to be involved in ANGIOGENESIS, including RAF KINASES and VEGF RECEPTORS. It is used in the treatment of advanced RENAL CELL CARCINOMA and HEPATOCELLULAR CARCINOMA, and for treatment of THYROID CARCINOMA refractory to radioactive iodine therapy. 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate,BAY 43-9006,BAY 545-9085,BAY-545-9085,BAY-673472,Nexavar,Sorafenib N-Oxide,Sorafenib Tosylate,BAY 43 9006,BAY 439006,BAY 545 9085,BAY 5459085,BAY 673472,BAY5459085,Sorafenib N Oxide
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Theodore S Nowicki, and Augustine L Moscatello, and Edward Shin, and Stimson Schantz, and Raj K Tiwari, and Jan Geliebter
The urokinase plasminogen activator system in cancer: a putative therapeutic target?
March 2008, Drug news & perspectives,
Theodore S Nowicki, and Augustine L Moscatello, and Edward Shin, and Stimson Schantz, and Raj K Tiwari, and Jan Geliebter
Urokinase plasminogen activator system as a potential target for cancer therapy.
November 2009, Future oncology (London, England),
Theodore S Nowicki, and Augustine L Moscatello, and Edward Shin, and Stimson Schantz, and Raj K Tiwari, and Jan Geliebter
Role of urokinase plasminogen activator receptor in gastric cancer: a potential therapeutic target.
June 2012, Cancer biotherapy & radiopharmaceuticals,
Theodore S Nowicki, and Augustine L Moscatello, and Edward Shin, and Stimson Schantz, and Raj K Tiwari, and Jan Geliebter
The urokinase plasminogen activator system: a target for anti-cancer therapy.
February 2009, Current cancer drug targets,
Theodore S Nowicki, and Augustine L Moscatello, and Edward Shin, and Stimson Schantz, and Raj K Tiwari, and Jan Geliebter
The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies.
January 2016, Expert opinion on therapeutic targets,
Theodore S Nowicki, and Augustine L Moscatello, and Edward Shin, and Stimson Schantz, and Raj K Tiwari, and Jan Geliebter
Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.
March 2022, Journal of translational medicine,
Theodore S Nowicki, and Augustine L Moscatello, and Edward Shin, and Stimson Schantz, and Raj K Tiwari, and Jan Geliebter
Urokinase type plasminogen activator receptor (uPAR) as a new therapeutic target in cancer.
November 2016, Translational medicine @ UniSa,
Theodore S Nowicki, and Augustine L Moscatello, and Edward Shin, and Stimson Schantz, and Raj K Tiwari, and Jan Geliebter
Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid.
November 1998, The Journal of pathology,
Theodore S Nowicki, and Augustine L Moscatello, and Edward Shin, and Stimson Schantz, and Raj K Tiwari, and Jan Geliebter
Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
April 2002, Biochemical Society transactions,
Theodore S Nowicki, and Augustine L Moscatello, and Edward Shin, and Stimson Schantz, and Raj K Tiwari, and Jan Geliebter
The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
January 1998, Breast cancer research and treatment,
Copied contents to your clipboard!